These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 1536698)

  • 1. Penicillamine in rheumatoid arthritis. A problem of toxicity.
    Taylor HG; Samanta A
    Drug Saf; 1992; 7(1):46-53. PubMed ID: 1536698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longterm followup of treatment with D-penicillamine for rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens.
    Moens HJ; Ament BJ; Feltkamp BW; van der Korst JK
    J Rheumatol; 1987 Dec; 14(6):1115-9. PubMed ID: 3437418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic markers in rheumatoid arthritis relationship to toxicity from D-penicillamine.
    Stockman A; Zilko PJ; Major GA; Tait BD; Property DN; Mathews JD; Hannah MC; McCluskey J; Muirden KD
    J Rheumatol; 1986 Apr; 13(2):269-73. PubMed ID: 3459889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis.
    Wooley PH; Griffin J; Panayi GS; Batchelor JR; Welsh KI; Gibson TJ
    N Engl J Med; 1980 Aug; 303(6):300-2. PubMed ID: 6770269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA antigens and toxicity to gold and penicillamine in rheumatoid arthritis.
    Scherak O; Smolen JS; Mayr WR; Mayrhofer F; Kolarz G; Thumb NJ
    J Rheumatol; 1984 Oct; 11(5):610-4. PubMed ID: 6439866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3.
    Emery P; Panayi GS; Huston G; Welsh KI; Mitchell SC; Shah RR; Idle JR; Smith RL; Waring RH
    J Rheumatol; 1984 Oct; 11(5):626-32. PubMed ID: 6334741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis.
    Kean WF; Dwosh IL; Anastassiades TP; Ford PM; Kelly HG
    Arthritis Rheum; 1980 Feb; 23(2):158-64. PubMed ID: 7362666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulphasalazine in rheumatoid arthritis: combination therapy with D-penicillamine or sodium aurothiomalate.
    Farr M; Kitas G; Bacon PA
    Clin Rheumatol; 1988 Jun; 7(2):242-8. PubMed ID: 2901303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse effects of D-penicillamine in rheumatoid arthritis.
    Stein HB; Patterson AC; Offer RC; Atkins CJ; Teufel A; Robinson HS
    Ann Intern Med; 1980 Jan; 92(1):24-9. PubMed ID: 7350870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-DR antigens and proteinuria induced by aurothioglucose and D-penicillamine in patients with rheumatoid arthritis.
    Speerstra F; Reekers P; van de Putte LB; Vandenbroucke JP; Rasker JJ; de Rooij DJ
    J Rheumatol; 1983 Dec; 10(6):948-53. PubMed ID: 6420562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penicillamine-induced proteinuria: risk factors.
    Stein HB; Schroeder ML; Dillon AM
    Semin Arthritis Rheum; 1986 May; 15(4):282-7. PubMed ID: 3487119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic survey of HLA-A,B,C and D antigens and drug toxicity in rheumatoid arthritis.
    Dequeker J; Van Wanghe P; Verdickt W
    J Rheumatol; 1984 Jun; 11(3):282-6. PubMed ID: 6376799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity of longterm low dose D-penicillamine therapy in rheumatoid arthritis. Cooperative Systematic Studies of Rheumatic Disease Group.
    J Rheumatol; 1987 Feb; 14(1):67-73. PubMed ID: 2952797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penicillamine in rheumatoid arthritis: adverse effects.
    Hill HF
    Scand J Rheumatol Suppl; 1979; (28):94-9. PubMed ID: 156393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HLA system and complications of the treatment of rheumatoid polyarthritis with D-penicillamine].
    Bardin T; Dryll A; Ryckewaert A
    Rev Rhum Mal Osteoartic; 1986 Jan; 53(1):27-9. PubMed ID: 3486448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The side effects of penicillamine therapy in rheumatoid arthritis.
    Huskisson EC
    J Rheumatol Suppl; 1981; 7():146-8. PubMed ID: 6939876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of D-penicillamine by multicentric double-blind comparative study in chronic rheumatoid arthritis.
    Shiokawa Y; Horiuchi Y; Honma M; Kageyama T; Okada T; Azuma T
    Arthritis Rheum; 1977; 20(8):1464-72. PubMed ID: 144507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [D-penicillamine--side effects, pathogenesis and decreasing the risks].
    Grasedyck K
    Z Rheumatol; 1988; 47 Suppl 1():17-9. PubMed ID: 3063003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of previous gold toxicity on subsequent development of penicillamine toxicity.
    Smith PJ; Swinburn WR; Swinson DR; Stewart IM
    Br Med J (Clin Res Ed); 1982 Aug 28-Sep 4; 285(6342):595-6. PubMed ID: 6218857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lichenoid lesions of the oral mucosa in rheumatoid arthritis patients treated with penicillamine.
    Blasberg B; Dorey JL; Stein HB; Chalmers A; Conklin RJ
    J Rheumatol; 1984 Jun; 11(3):348-51. PubMed ID: 6737375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.